These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9154316)

  • 1. Megakaryocytes and platelets in myeloproliferative disorders.
    Briere J; Kiladjian JJ; Peynaud-Debayle E
    Baillieres Clin Haematol; 1997 Feb; 10(1):65-88. PubMed ID: 9154316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dysmegakaryocytopoiesis and dysthrombopoiesis in myeloproliferative syndromes].
    Brière J; Kiladjian JJ; Peynaud-Debayle E
    C R Seances Soc Biol Fil; 1996; 190(5-6):533-9. PubMed ID: 9074718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.
    Yan L; Elkassar N; Gardin C; Briere J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():31-40. PubMed ID: 8951770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythaemia, polycythaemia vera and chronic megakaryocytic granulocytic metaplasia.
    Michiels JJ
    Neth J Med; 1997 Aug; 51(2):57-64. PubMed ID: 9286142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
    Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
    Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).
    Michiels JJ; Thiele J
    Int J Hematol; 2002 Aug; 76(2):133-45. PubMed ID: 12215011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric analysis of megakaryocyte ploidy in chronic myeloproliferative disorders and reactive thrombocytosis.
    Jacobsson S; Carneskog J; Ridell B; Wadenvik H; Swolin B; Kutti J
    Eur J Haematol; 1996 May; 56(5):287-92. PubMed ID: 8641402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ; Juvonen E
    Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 10. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders.
    Li Y; Hetet G; Kiladjian JJ; Gardin C; Grandchamp B; Briere J
    Br J Haematol; 1996 Jan; 92(1):60-6. PubMed ID: 8562412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.
    Martyré MC
    Leuk Lymphoma; 1995 Dec; 20(1-2):39-44. PubMed ID: 8750621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis--features of significance for the diagnosis of primary (essential) thrombocythaemia.
    Thiele J; Schneider G; Hoeppner B; Wienhold S; Zankovich R; Fischer R
    Virchows Arch A Pathol Anat Histopathol; 1988; 413(5):407-17. PubMed ID: 3140482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
    Spivak JL
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF.
    Li Y; Hetet G; Maurer AM; Chait Y; Dhermy D; Briere J
    Br J Haematol; 1994 Jul; 87(3):471-6. PubMed ID: 7993786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous measurement of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia.
    Elliot MA; Yoon SY; Kao P; Li CY; Tefferi A
    Eur J Haematol; 2002 Mar; 68(3):175-9. PubMed ID: 12068799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders.
    Matolcsy A; Nádor R; Wéber E; Kónya T
    Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):441-5. PubMed ID: 1375798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.